Date/Time | Presentation Title | Lead Author | |
June 01, 2010 8:40 8:50AM PT | An integrated summary of the results of two pivotal phase III studies of PSD502 for premature ejaculation (PE) | Ira D. Sharlip, MD, University of California at San Francisco, San Francisco, CA | |
June 01, 2010 8:50 9:00AM PT | Does time matter? Determination of the relationship between increasing ejaculatory latency in men with premature ejaculation and the domains of the index of premature ejaculation (IPE) | Stanley E. Althof, PhD, University of Miami Miller School of Medicine, West Palm Beach, FL | |
June 01, 2010 11:10 11:20AM PT | PSD502: A second phase III, randomized, double-blind, placebo-controlled study in premature ejaculation (PE) patients in the US and Europe | Culley C. Carson, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC | |
June 01, 2010 11:20 11:30AM PT | PSD502 appears to be effective in both circumcised and un-circumcised men with premature ejaculation (PE) | Wayne Hellstrom, MD, FACS, Tulane University School of Medicine, New Orleans, LA | |
June 01, 2010 1:50 2:00PM PT | Efficacy is maintained and may be enhanced using long-term (1yr) administration of PSD502 for premature ejaculation (PE) | Michael A. Perelman, PhD, New York Presbyterian Hospital, New York, NY | |
